← Leaderboards
Carol J Fabian
University Of Kansas Medical Center
$11,007,875
Attributed
$11,007,875
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $852.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,007,875 · 6
By mechanism
R01$5,926,685 · 2
U01$4,270,053 · 1
R21$811,137 · 2
N01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Kansas Medical Center
Same institution · by research overlap
- Sudhansu K Dey$18,014,179
- Danny R Welch$4,556,425
- Lauren Elizabeth Nye$135,951
Others in their field
Top investigators on “Chemoprevention”
- Charles A Coltman · Southwest Oncology Group$144,723,158
- Norman Wolmark · Nsabp Foundation, Inc.$110,141,959
- John Anthony Baron · Dartmouth College$61,176,184
- Fred M Gordin · Social And Scientific Systems, Inc.$50,695,408
- Caroline C Sigman · Ccs Associates, Inc.$26,419,788
- Jonathan White · Midwest Research Institute$24,635,824
Research focus
ChemopreventionHigh Risk WomanSerumBenignWomanBreastPilot ProjectsFine Needle Aspiration BiopsyMammary Gland ParenchymaRisk ReductionPostmenopauseEstrogensTissuesTestosteroneBiological MarkersClinical TrialsFrightGenesPlacebo ControlQuality Of LifeHormonesPlacebosBaseHot Flushes
Grant awards (19)
Biomarker-Based Phase IIB Trial of (Bazedoxifene-Conjugated Estrogen) to Reduce Risk for Breast Cancer$825,302
R01 · FY2025 · CA · contact PI
Biomarker-Based Phase IIB Trial of (Bazedoxifene-Conjugated Estrogen) to Reduce Risk for Breast Cancer$793,304
R01 · FY2024 · CA · contact PI
Biomarker-Based Phase IIB Trial of (Bazedoxifene-Conjugated Estrogen) to Reduce Risk for Breast Cancer$832,556
R01 · FY2023 · CA · contact PI
Biomarker-Based Phase IIB Trial of (Bazedoxifene-Conjugated Estrogen) to Reduce Risk for Breast Cancer$840,045
R01 · FY2022 · CA · contact PI
Biomarker-Based Phase IIB Trial of (Bazedoxifene-Conjugated Estrogen) to Reduce Risk for Breast Cancer$852,459
R01 · FY2021 · CA · contact PI
Breast Cancer Prevention by Letrozole in High Risk Women$340,081
R01 · FY2010 · CA · contact PI
Breast Cancer Prevention by Letrozole in High Risk Women$475,727
R01 · FY2009 · CA · contact PI
Breast Cancer Prevention by Letrozole in High Risk Women$473,412
R01 · FY2008 · CA · contact PI
Breast Cancer Risk Biomarkers and Energy Balance$147,000
R21 · FY2008 · CA · contact PI
Breast Cancer Prevention by Letrozole in High Risk Women$493,799
R01 · FY2007 · CA · contact PI
Breast Cancer Risk Biomarkers and Energy Balance$176,400
R21 · FY2007 · CA · contact PI
FlaxSeed Lignan for Breast Cancer Chemoprevention$145,554
R21 · FY2007 · CA · contact PI
FlaxSeed Lignan for Breast Cancer Chemoprevention$152,553
R21 · FY2006 · CA · contact PI
FlaxSeed Lignan for Breast Cancer Chemoprevention$189,630
R21 · FY2005 · CA
CHEMOPREVENTION FOR WOMEN AT HIGH RISK OF BREAST CANCER$470,369
U01 · FY2003 · CA
CHEMOPREVENTION FOR WOMEN AT HIGH RISK OF BREAST CANCER$1,793,476
U01 · FY2002 · CA
CHEMOPREVENTION FOR WOMEN AT HIGH RISK OF BREAST CANCER$1,760,323
U01 · FY2001 · CA
CHEMOPREVENTION FOR WOMEN AT HIGH RISK OF BREAST CANCER$245,885
U01 · FY2000 · CA
PHASE I NONRANDOMIZED STUDY OF AN ANTIESTROGEN IN WOMEN$0
N01 · FY2000 · CN